StockData

Ironwood Pharmaceuticals vs MannKind

IRWD and MNKD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRWD and MNKD compare

MannKind is the larger company, worth 1.6 times as much as Ironwood Pharmaceuticals ($1.3B against $801M).

MannKind grew revenue faster over the last twelve months (30.5% versus 26.2% for Ironwood Pharmaceuticals).

Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −11.1% at MannKind.

Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRWDMNKD
Size and price
Market cap$801M$1.3B
Share price$4.85$4.07
Change, 1 year43.9%−19.6%
Change, 5 years−56.5%−12.1%
Beta (5Y)1.051.98
Employees100241
StockData Score
Total score12 (better)6
Valuation score6 (better)1
Growth score22
Performance score22
Health score2 (better)1
Dividend score00
Valuation
P/E6.3×–
P/S2.1× (better)3.3×
EV/EBITDA3.1× (better)39.8×
FCF yield–−1.4%
Fair value$12.87$1.79
Margin of safety62.3% (better)−127%
Growth
Revenue growth (TTM)26.2%30.5% (better)
Revenue growth, 5Y average−5.3%39.9% (better)
Net income growth (TTM)–−233%
EPS growth (TTM)–−218%
EPS growth, 5Y average−25.6%–
Profitability
Gross margin–89.8%
Operating margin60.1% (better)2.3%
Net margin33.4% (better)−11.1%
FCF margin–−4.6%
Financial health
Interest coverage7.2× (better)0.3×
Current ratio6.06 (better)1.72
Altman Z-score−1.91 (better)−4.45
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.2%56.7%
Held by insiders16.0%2.5%
Insider net buying, 12 months−$22.6M−$2.9M (better)
Short interest, % of float10.7%8.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.